{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:51:47Z","timestamp":1787021507892,"version":"build-2736575974"},"reference-count":34,"publisher":"Japanese Society of Veterinary Science","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Vet. Med. Sci.","The Journal of Veterinary Medical Science"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1292\/jvms.23-0200","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:28:44Z","timestamp":1696876124000},"page":"1261-1268","source":"Crossref","is-referenced-by-count":9,"title":["Safety and pharmacokinetics of thalidomide in tumor-bearing dogs"],"prefix":"10.1292","volume":"85","author":[{"given":"Fukiko","family":"MATSUYAMA","sequence":"first","affiliation":[{"name":"Japan Small Animal Cancer Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyoshi","family":"FUJITA","sequence":"additional","affiliation":[{"name":"Gunma Prefectural Cancer Center, Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"FUKAZAWA","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"KOBAYASHI","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"122","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bray JP, Munday JS. 2020. Thalidomide reduces vascular endothelial growth factor immunostaining in canine splenic hemangiosarcoma. Vet Sci<\/i> 7: 67.","DOI":"10.3390\/vetsci7020067"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bray JP, Orbell G, Cave N, Munday JS. 2018. Does thalidomide prolong survival in dogs with splenic haemangiosarcoma?J Small Anim Pract<\/i> 59: 85\u201391.","DOI":"10.1111\/jsap.12796"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. de Campos CB, Lavalle GE, Fialho Lig\u00f3rio S, Camargo Nunes F, Carneiro RA, Amorim RL, Cassali GD. 2016. Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas. Vet Rec<\/i> 179: 514.","DOI":"10.1136\/vr.103764"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. DE Campos CB, Lavalle GE, Monteiro LN, P\u00eagas GRA, Fialho SL, Balabram D, Cassali GD. 2018. Adjuvant Thalidomide and Metronomic Chemotherapy for the Treatment of Canine Malignant Mammary Gland Neoplasms. In Vivo<\/i> 32: 1659\u20131666.","DOI":"10.21873\/invivo.11429"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA<\/i> 91: 4082\u20134085.","DOI":"10.1073\/pnas.91.9.4082"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Desimoni E, Brunetti B. 2015. About Estimating the limit of detection by the signal to noise approach. Pharm Anal Acta<\/i> 6: 355.","DOI":"10.4172\/2153-2435.1000355"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. 2000. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol<\/i> 18: 708\u2013715.","DOI":"10.1200\/JCO.2000.18.4.708"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fujita Y, Yamamoto K, Aomori T, Murakami H, Horiuchi R. 2008. [Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese, Mexican and British companies]. Yakugaku Zasshi<\/i> 128: 1449\u20131457.","DOI":"10.1248\/yakushi.128.1449"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. 2005. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut<\/i> 54: 540\u2013545.","DOI":"10.1136\/gut.2004.047563"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Guti\u00e9rrez-Rodr\u00edguez O. 1984. Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum<\/i> 27: 1118\u20131121.","DOI":"10.1002\/art.1780271006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hanje AJ, Shamp JL, Thomas FB, Meis GM. 2006. Thalidomide-induced severe hepatotoxicity. Pharmacotherapy<\/i> 26: 1018\u20131022.","DOI":"10.1592\/phco.26.7.1018"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, V\u00f6lcker HE. 1998. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol<\/i> 236: 461\u2013466.","DOI":"10.1007\/s004170050106"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lenz W. 1962. Thalidomide and congenital abnormalities. Lancet<\/i> 1: 45.","DOI":"10.1016\/S0140-6736(62)92665-X"},{"key":"14","unstructured":"14. Lenz W. 1985. Thalidomide embryopathy in Germany, 1959\u20131961. Prog Clin Biol Res<\/i> 163C: 77\u201383."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Leroy BE, Northrup N. 2009. Prostate cancer in dogs: comparative and clinical aspects. Vet J<\/i> 180: 149\u2013162.","DOI":"10.1016\/j.tvjl.2008.07.012"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Levesque E, Bradette M. 2009. Hepatotoxicity as a rare but serious side effect of thalidomide. Ann Hematol<\/i> 88: 183\u2013184.","DOI":"10.1007\/s00277-008-0559-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mas A, Blackwood L, Cripps P, Murphy S, De Vos J, Dervisis N, Martano M, Polton GA. 2011. Canine tonsillar squamous cell carcinoma -- a multi-centre retrospective review of 44 clinical cases. J Small Anim Pract<\/i> 52: 359\u2013364.","DOI":"10.1111\/j.1748-5827.2011.01075.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Matthews SJ, McCoy C. 2003. Thalidomide: a review of approved and investigational uses. Clin Ther<\/i> 25: 342\u2013395.","DOI":"10.1016\/S0149-2918(03)80085-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mellin GW, Katzenstein M. 1962. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med<\/i> 267: 1238\u20131244.","DOI":"10.1056\/NEJM196212132672407"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD. 2001. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve<\/i> 24: 1050\u20131057.","DOI":"10.1002\/mus.1109"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Murakami H, Shimizu K, Sawamura M, Suzuki K, Sugiura I, Kosugi H, Shimazaki C, Taniwaki M, Abe M, Takagi T. 2009. Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed\/refractory multiple myeloma. Int J Hematol<\/i> 89: 636\u2013641.","DOI":"10.1007\/s12185-009-0314-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. No authors listed. 2016. Veterinary cooperative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol<\/i> 14: 417\u2013446.","DOI":"10.1111\/vco.283"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Noormohamed FH, Youle MS, Higgs CJ, Kook KA, Hawkins DA, Lant AF, Thomas SD. 1999. Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. AIDS Res Hum Retroviruses<\/i> 15: 1047\u20131052.","DOI":"10.1089\/088922299310331"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Pierini A, Sartini I, Giorgi M, \u0141ebkowska-Wieruszewska B, Lisowski A, Poapolathep A, Marchetti V. 2020. Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. J Vet Sci<\/i> 21: e60.","DOI":"10.4142\/jvs.2020.21.e60"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Polton G, Finotello R, Sabattini S, Rossi F, Laganga P, Vasconi ME, Barbanera A, Stiborova K, Rohrer Bley C, Marconato L. 2018. Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide. Vet Comp Oncol<\/i> 16: 399\u2013408.","DOI":"10.1111\/vco.12393"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Rossi F, Sabattini S, Vascellari M, Marconato L. 2018. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma. Vet Comp Oncol<\/i> 16: 497\u2013504.","DOI":"10.1111\/vco.12407"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. 1991. Thalidomide selectively inhibits tumor necrosis factor \u03b1 production by stimulated human monocytes. J Exp Med<\/i> 173: 699\u2013703.","DOI":"10.1084\/jem.173.3.699"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Scheffler MR, Colburn W, Kook KA, Thomas SD. 1999. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics. Clin Pharmacol Ther<\/i> 65: 483\u2013490.","DOI":"10.1016\/S0009-9236(99)70067-6"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sheskin J. 1965. Further observation with thalidomide in lepra reactions. Lepr Rev<\/i> 36: 183\u2013187.","DOI":"10.5935\/0305-7518.19650036"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. 1999. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med<\/i> 341: 1565\u20131571.","DOI":"10.1056\/NEJM199911183412102"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Tabata K, Yamaoka K, Kaibara A, Suzuki S, Terakawa M, Hata T. 1999. Moment analysis program available on Microsoft Excel\u00ae<\/sup>. Xenobio. Metabol. and Dispos.<\/i> 14: 286\u2013293.","DOI":"10.2133\/dmpk.14.286"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Teo SK, Evans MG, Brockman MJ, Ehrhart J, Morgan JM, Stirling DI, Thomas SD. 2001. Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs. Toxicol Sci<\/i> 59: 160\u2013168.","DOI":"10.1093\/toxsci\/59.1.160"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Teo SK, Scheffler MR, Kook KA, Tracewell WG, Colburn WA, Stirling DI, Thomas SD. 2001. Thalidomide dose proportionality assessment following single doses to healthy subjects. J Clin Pharmacol<\/i> 41: 662\u2013667.","DOI":"10.1177\/00912700122010555"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Wettstein AR, Meagher AP. 1997. Thalidomide in Crohn\u2019s disease. Lancet<\/i> 350: 1445\u20131446.","DOI":"10.1016\/S0140-6736(05)64206-7"}],"container-title":["Journal of Veterinary Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/85\/12\/85_23-0200\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T22:15:36Z","timestamp":1702073736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/85\/12\/85_23-0200\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1292\/jvms.23-0200","relation":{},"ISSN":["0916-7250","1347-7439"],"issn-type":[{"value":"0916-7250","type":"print"},{"value":"1347-7439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"23-0200"}}